TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Time to Achieve Complete Remission (CR) After Sunitinib Initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Nephrectomy From Diagnosis of Metastatic Renal Cell Carcinoma (mRCC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Osteopathic structural exam findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: final infarction size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quantification of inflammation in sickle cell disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Efficiency of Phosphodiesterase inhibitor on neutrophil adhesion in Sickle cell disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Study of iron metabolism in Diamond-Blackfan Anemia patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Pleth Variability Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes From Screening in the Results of the Physical Examination That Are Clinically Significant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes From Screening in the Results of the Laboratory Evaluations That Are Clinically Significant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes From Screening in the Results of the Electrocardiograms (ECGs) That Are Clinically Significant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes From Screening in the Vital Signs That Are Clinically Significant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical Intraepithelial neoplasia (CIN) 2/3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: aesthetic satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of post surgery chronic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in soft tissue pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BR55 sensitivity assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Severe Oral Mucositis (WHO Grade 3 and 4)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Healthy Snacks Purchased
Endpoint domain: Life impact
Endpoint subdomain: Nutrition
Primary endpoint: Intent to screen the colon
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change From Baseline in the Total Blepharoconjunctivitis Grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration of selitrectinib in plasma in fasted state (Cmax_fasted)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve of selitrectinib in plasma from time 0 to 24 hours in fasted state (AUC(0-24)_fasted)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve of selitrectinib in plasma from time 0 to infinity in fasted state (AUC_fasted)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dendritic cell subgroup changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Myocardial salvage index reproducibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: grade of fatty liver disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in neural responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in supine systolic blood pressure (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in supine diastolic blood pressure (DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximum increase in supine pulse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prescribing error
Endpoint domain: Adverse events/effects
Primary endpoint: Effectiveness of treatment based on cellulite classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of corporal measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hepatitis C prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Frequencies of Th1 in peripheral blood and gut mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequencies of Th17 in peripheral blood and gut mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequencies of Th22 in peripheral blood and gut mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of Insomnia
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in mean steps/day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety concerns of Quercetin supplementation
Endpoint domain: Adverse events/effects
Primary endpoint: Change in FACIT-TS questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ratio of patient-reported intake of oral opioids to prescribed amount
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: new myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: severe recurrent ischemia requiring urgent revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ability to perform the TUG test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of BRAFV600E alleles in tumor tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mastectomy Skin Flap Necrosis
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of financial toxicity
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: skinfolds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Completion of Training Intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Facility Implementation of Trainings
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants in Pilot Surveys
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants in Pilot Interviews
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of patients with confirmed primary aldosteronism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of responding children with adequate control of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in total lean body mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: best radiological tumoral response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: biological response rate defined by value of PSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Fold Increase From Baseline in Serum HI Antibody Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tendon length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Bleeding Requiring Intervention After Initial Hemostasis Achieved
Endpoint domain: Adverse events/effects
Primary endpoint: Bleeding Requiring Intervention Post-CATH Day 1
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of complications following spilled gallstones
Endpoint domain: Adverse events/effects
Primary endpoint: CgH frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total dose of intervention received
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Plasma gastrin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Sub-cutaneous late toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of achieved immunity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Muscarinic M2 receptor mRNA expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Patients With a Detectable Cytolytic T Lymphocyte (CTL) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin A
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in physical activity minutes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Prevalence of thromboembolic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Coagulation parameters variations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: number of workers with labial injuries
Endpoint domain: Adverse events/effects
Primary endpoint: Non-progression rate after 6 months of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 30-s chair stand performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Consistently Attending and Completing Four Neuroimaging Sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Response to Chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADHD Symptoms Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADHD Impairment Change
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Efficacy of therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Subjects with Lupus Low Disease Activity Score (LLDAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects with Systemic Lupus Erythematosus Responder Index - 4 (SRI-4) response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects with Treatment-Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Documented Medication Errors
Endpoint domain: Adverse events/effects
Primary endpoint: Change in IgE-blocking factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Chair side time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intestinal Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Identification of lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Identification of affected area in node
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Patient Reported Frequency of Recurring PSVT Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient Reported Duration of Recurring PSVT Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient Reported Severity of Recurring PSVT Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: sensory organization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rhythmic weight shifting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: limits of stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with A1c <6.5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: WOMAC Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: WOMAC Function Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: WOMAC Stiffness Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of postextubation distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol Consequences
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Risk-taking
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of individuals progressing to meet RDS criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Complete remission without relapse
Endpoint domain: Mortality/survival
Primary endpoint: First time of asthma exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Patients with treatment-related major bleeding event
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Quality of Life (FACT-An Anemia scale)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Colony Forming Units (CFU) percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of sepsis in preterm infants by blood group
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: proportion of patients who will experience clinical success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low Cervical spine lordosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid Urine Test Positive Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Entry Into Treatment for Opioid Use Disorder
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Knee Injury and Osteoarthritis Outcome Score (KOOS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal Parenting Competence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Correlation of changes in FFM with survival at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of lymphocytopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Ex vivo leukocyte function measured by ROS production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Primary surgical margin status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in functional ambulation category point
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Calprotectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: High degree AV blocks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Knowledge Gain Scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Communication Rating Scores
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: BPSD Reports
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants maintaining SVR at Week 144
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in anxiety intensity scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 2-year readmission rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: mobility of sepsis survivors
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean Change in Visual Acuity (LogMAR) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total stroke rate
Endpoint domain: Mortality/survival
Primary endpoint: Safety and tolerability of OTO-104
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy on handicaps
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in smoking cessation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Levels of Homocysteine, Glutathione, and the Ratio of Aβ42 to Aβ40
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean rate of change of FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lunch Plasma Glucose Time 0 Corrected AUC (0-240)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Breakfast Plasma Glucose Time 0 Corrected AUC (0-240)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lunch Plasma Glucose Excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain measurement using digitalized pain pressure algometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Western Ontario and Mc Master Universities Osteoarthritis Index (WOMAC)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: D-dimers concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Visual Analog Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline in VISA-A score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number and percent of patients achieving 65-85% heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: IKDC 2000
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Muscle power (N.m/kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proprioception (degree)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of skin and/or gastrointestinal toxicity CTCAE grade 4 at 4 months
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in tremor severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area Under the glycemia Curve over 120 min (AUC 0-120min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pantothenic acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage time below 3.0mmol/L (54mg/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage time in range 4-10mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Assessment of Overweight in Children and Adolescents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Static physicians global assessment (PGA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life as measured by DLQI
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Diagnosis rate of acute kidney injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rate of dialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 30-Day Freedom From Major Adverse Cardiac Events (MACE)
Endpoint domain: Adverse events/effects
Primary endpoint: TEE results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Melasma area and severity index (MASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Antera 3D skin test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: VISIA image analysis system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Occurrence of Haemophilus influenzae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of High Grade Radiation Dermatitis
Endpoint domain: Adverse events/effects
Primary endpoint: Median Change in Quality of Life Scoring
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of patients achieving PASI score <1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of patients achieving PASI score <2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of patients achieving PASI score <3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of patients achieving PASI score <5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Post operative resolution of motor block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: PO hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital